Cherwell Releases New Redipor Prepared Microbiological Media Product Information
Cherwell Laboratories has announced the availability of its 2015 Redipor prepared microbiological media price list. The extensive Redipor range, manufactured at Cherwell’s ISO9001 registered site in Bicester offers ready-to-use media, including Petri dishes, contact plates, bottles and broth bags, designed to meet the rigorous requirements of the pharmaceutical and related industries.
With over 40 years’ experience, Cherwell has built a strong reputation for providing high-quality products alongside a friendly, customer-focused service. Despite significant company growth, fuelled by increasing demand for Redipor prepared media throughout the UK and across Europe, Cherwell have retained flexible production methods and managed stock levels, ensuring they can continue to deliver cost effective, timely solutions for customers.
Offering an extensive selection of both industry standard products and those with a unique formulation or presentation, the Redipor range provides a flexible solution for environmental monitoring, sterility testing of products, operator validation and process validation. The range includes petri dishes (55 mm, 90 mm and 140 mm) and contact plates, plus bottled media, broth bags and ampoules, with all products subjected to a full array of QC tests, including comprehensive growth tests. Cherwell can also discuss specific requirements and work with individual customers to ensure their needs are met.
“As a family-owned business, we understand the importance of maintaining good communication and relations with all our customers to ensure we continue to meet their exact requirements,” said Andy Whittard, Managing Director, Cherwell Laboratories. “Over the years, the reputation of the Redipor brand has been built on our flexibility and willingness to adapt efficiently to changes in both customer and regulatory expectations.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.